0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Restless Legs Syndrome Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-37O3937
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Restless Legs Syndrome Market Insights and Forecast to 2028
BUY CHAPTERS

Global Restless Legs Syndrome Market Research Report 2024

Code: QYRE-Auto-37O3937
Report
February 2024
Pages:89
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Restless Legs Syndrome Market

Restless legs syndrome (RLS) is a neurological disease. RLS is also called as Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible desire to move their feet. The continual movement of the legs leads to pain in the limbs, which leads to the unusual sleep pattern of patients.
The global Restless Legs Syndrome market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
Global key players of Restless Legs Syndrome include Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, etc.
Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.
This report aims to provide a comprehensive presentation of the global market for Restless Legs Syndrome, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Restless Legs Syndrome.

Report Scope

The Restless Legs Syndrome market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Restless Legs Syndrome market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Restless Legs Syndrome companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Restless Legs Syndrome Market Report

Report Metric Details
Report Name Restless Legs Syndrome Market
Segment by Type
  • Pharmacological Therapy
  • Non-Pharmacological Therapy
Segment by Application
  • Below 35 Years Old
  • From 35 to 50 Years Old
  • Above 50 Years Old
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, Manhattan Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Restless Legs Syndrome companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

What is the Boehringer Ingelheim GmbH share in Restless Legs Syndrome Market?

Ans: Boehringer Ingelheim GmbH is the largest manufacturers of Restless Legs Syndrome in the world, has a share about 70%.

Who are the main players in the Restless Legs Syndrome Market report?

Ans: The main players in the Restless Legs Syndrome Market are Boehringer Ingelheim GmbH, UCB SA, Astellas, Arbor Pharmaceuticals, GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG, Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation, Manhattan Pharmaceuticals

What are the Application segmentation covered in the Restless Legs Syndrome Market report?

Ans: The Applications covered in the Restless Legs Syndrome Market report are Below 35 Years Old, From 35 to 50 Years Old, Above 50 Years Old

What are the Type segmentation covered in the Restless Legs Syndrome Market report?

Ans: The Types covered in the Restless Legs Syndrome Market report are Pharmacological Therapy, Non-Pharmacological Therapy

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Restless Legs Syndrome Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pharmacological Therapy
1.2.3 Non-Pharmacological Therapy
1.3 Market by Application
1.3.1 Global Restless Legs Syndrome Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Below 35 Years Old
1.3.3 From 35 to 50 Years Old
1.3.4 Above 50 Years Old
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Restless Legs Syndrome Market Perspective (2019-2030)
2.2 Restless Legs Syndrome Growth Trends by Region
2.2.1 Global Restless Legs Syndrome Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Restless Legs Syndrome Historic Market Size by Region (2019-2024)
2.2.3 Restless Legs Syndrome Forecasted Market Size by Region (2025-2030)
2.3 Restless Legs Syndrome Market Dynamics
2.3.1 Restless Legs Syndrome Industry Trends
2.3.2 Restless Legs Syndrome Market Drivers
2.3.3 Restless Legs Syndrome Market Challenges
2.3.4 Restless Legs Syndrome Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Restless Legs Syndrome Players by Revenue
3.1.1 Global Top Restless Legs Syndrome Players by Revenue (2019-2024)
3.1.2 Global Restless Legs Syndrome Revenue Market Share by Players (2019-2024)
3.2 Global Restless Legs Syndrome Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Restless Legs Syndrome Revenue
3.4 Global Restless Legs Syndrome Market Concentration Ratio
3.4.1 Global Restless Legs Syndrome Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Restless Legs Syndrome Revenue in 2023
3.5 Restless Legs Syndrome Key Players Head office and Area Served
3.6 Key Players Restless Legs Syndrome Product Solution and Service
3.7 Date of Enter into Restless Legs Syndrome Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Restless Legs Syndrome Breakdown Data by Type
4.1 Global Restless Legs Syndrome Historic Market Size by Type (2019-2024)
4.2 Global Restless Legs Syndrome Forecasted Market Size by Type (2025-2030)
5 Restless Legs Syndrome Breakdown Data by Application
5.1 Global Restless Legs Syndrome Historic Market Size by Application (2019-2024)
5.2 Global Restless Legs Syndrome Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Restless Legs Syndrome Market Size (2019-2030)
6.2 North America Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Restless Legs Syndrome Market Size by Country (2019-2024)
6.4 North America Restless Legs Syndrome Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Restless Legs Syndrome Market Size (2019-2030)
7.2 Europe Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Restless Legs Syndrome Market Size by Country (2019-2024)
7.4 Europe Restless Legs Syndrome Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Restless Legs Syndrome Market Size (2019-2030)
8.2 Asia-Pacific Restless Legs Syndrome Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Restless Legs Syndrome Market Size by Region (2019-2024)
8.4 Asia-Pacific Restless Legs Syndrome Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Restless Legs Syndrome Market Size (2019-2030)
9.2 Latin America Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Restless Legs Syndrome Market Size by Country (2019-2024)
9.4 Latin America Restless Legs Syndrome Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Restless Legs Syndrome Market Size (2019-2030)
10.2 Middle East & Africa Restless Legs Syndrome Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Restless Legs Syndrome Market Size by Country (2019-2024)
10.4 Middle East & Africa Restless Legs Syndrome Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Detail
11.1.2 Boehringer Ingelheim GmbH Business Overview
11.1.3 Boehringer Ingelheim GmbH Restless Legs Syndrome Introduction
11.1.4 Boehringer Ingelheim GmbH Revenue in Restless Legs Syndrome Business (2019-2024)
11.1.5 Boehringer Ingelheim GmbH Recent Development
11.2 UCB SA
11.2.1 UCB SA Company Detail
11.2.2 UCB SA Business Overview
11.2.3 UCB SA Restless Legs Syndrome Introduction
11.2.4 UCB SA Revenue in Restless Legs Syndrome Business (2019-2024)
11.2.5 UCB SA Recent Development
11.3 Astellas
11.3.1 Astellas Company Detail
11.3.2 Astellas Business Overview
11.3.3 Astellas Restless Legs Syndrome Introduction
11.3.4 Astellas Revenue in Restless Legs Syndrome Business (2019-2024)
11.3.5 Astellas Recent Development
11.4 Arbor Pharmaceuticals
11.4.1 Arbor Pharmaceuticals Company Detail
11.4.2 Arbor Pharmaceuticals Business Overview
11.4.3 Arbor Pharmaceuticals Restless Legs Syndrome Introduction
11.4.4 Arbor Pharmaceuticals Revenue in Restless Legs Syndrome Business (2019-2024)
11.4.5 Arbor Pharmaceuticals Recent Development
11.5 GlaxoSmithKline plc.
11.5.1 GlaxoSmithKline plc. Company Detail
11.5.2 GlaxoSmithKline plc. Business Overview
11.5.3 GlaxoSmithKline plc. Restless Legs Syndrome Introduction
11.5.4 GlaxoSmithKline plc. Revenue in Restless Legs Syndrome Business (2019-2024)
11.5.5 GlaxoSmithKline plc. Recent Development
11.6 Ligand Pharmaceuticals Incorporated
11.6.1 Ligand Pharmaceuticals Incorporated Company Detail
11.6.2 Ligand Pharmaceuticals Incorporated Business Overview
11.6.3 Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Introduction
11.6.4 Ligand Pharmaceuticals Incorporated Revenue in Restless Legs Syndrome Business (2019-2024)
11.6.5 Ligand Pharmaceuticals Incorporated Recent Development
11.7 axxonis Pharma AG
11.7.1 axxonis Pharma AG Company Detail
11.7.2 axxonis Pharma AG Business Overview
11.7.3 axxonis Pharma AG Restless Legs Syndrome Introduction
11.7.4 axxonis Pharma AG Revenue in Restless Legs Syndrome Business (2019-2024)
11.7.5 axxonis Pharma AG Recent Development
11.8 Kyowa Hakko Kirin Co.
11.8.1 Kyowa Hakko Kirin Co. Company Detail
11.8.2 Kyowa Hakko Kirin Co. Business Overview
11.8.3 Kyowa Hakko Kirin Co. Restless Legs Syndrome Introduction
11.8.4 Kyowa Hakko Kirin Co. Revenue in Restless Legs Syndrome Business (2019-2024)
11.8.5 Kyowa Hakko Kirin Co. Recent Development
11.9 Jazz Pharmaceuticals, Inc.
11.9.1 Jazz Pharmaceuticals, Inc. Company Detail
11.9.2 Jazz Pharmaceuticals, Inc. Business Overview
11.9.3 Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Introduction
11.9.4 Jazz Pharmaceuticals, Inc. Revenue in Restless Legs Syndrome Business (2019-2024)
11.9.5 Jazz Pharmaceuticals, Inc. Recent Development
11.10 Omeros Corporation
11.10.1 Omeros Corporation Company Detail
11.10.2 Omeros Corporation Business Overview
11.10.3 Omeros Corporation Restless Legs Syndrome Introduction
11.10.4 Omeros Corporation Revenue in Restless Legs Syndrome Business (2019-2024)
11.10.5 Omeros Corporation Recent Development
11.11 Manhattan Pharmaceuticals
11.11.1 Manhattan Pharmaceuticals Company Detail
11.11.2 Manhattan Pharmaceuticals Business Overview
11.11.3 Manhattan Pharmaceuticals Restless Legs Syndrome Introduction
11.11.4 Manhattan Pharmaceuticals Revenue in Restless Legs Syndrome Business (2019-2024)
11.11.5 Manhattan Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Restless Legs Syndrome Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Pharmacological Therapy
    Table 3. Key Players of Non-Pharmacological Therapy
    Table 4. Global Restless Legs Syndrome Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 5. Global Restless Legs Syndrome Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Restless Legs Syndrome Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global Restless Legs Syndrome Market Share by Region (2019-2024)
    Table 8. Global Restless Legs Syndrome Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global Restless Legs Syndrome Market Share by Region (2025-2030)
    Table 10. Restless Legs Syndrome Market Trends
    Table 11. Restless Legs Syndrome Market Drivers
    Table 12. Restless Legs Syndrome Market Challenges
    Table 13. Restless Legs Syndrome Market Restraints
    Table 14. Global Restless Legs Syndrome Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global Restless Legs Syndrome Market Share by Players (2019-2024)
    Table 16. Global Top Restless Legs Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Restless Legs Syndrome as of 2023)
    Table 17. Ranking of Global Top Restless Legs Syndrome Companies by Revenue (US$ Million) in 2023
    Table 18. Global 5 Largest Players Market Share by Restless Legs Syndrome Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Key Players Headquarters and Area Served
    Table 20. Key Players Restless Legs Syndrome Product Solution and Service
    Table 21. Date of Enter into Restless Legs Syndrome Market
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Restless Legs Syndrome Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global Restless Legs Syndrome Revenue Market Share by Type (2019-2024)
    Table 25. Global Restless Legs Syndrome Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global Restless Legs Syndrome Revenue Market Share by Type (2025-2030)
    Table 27. Global Restless Legs Syndrome Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global Restless Legs Syndrome Revenue Market Share by Application (2019-2024)
    Table 29. Global Restless Legs Syndrome Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global Restless Legs Syndrome Revenue Market Share by Application (2025-2030)
    Table 31. North America Restless Legs Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 32. North America Restless Legs Syndrome Market Size by Country (2019-2024) & (US$ Million)
    Table 33. North America Restless Legs Syndrome Market Size by Country (2025-2030) & (US$ Million)
    Table 34. Europe Restless Legs Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. Europe Restless Legs Syndrome Market Size by Country (2019-2024) & (US$ Million)
    Table 36. Europe Restless Legs Syndrome Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Asia-Pacific Restless Legs Syndrome Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Asia-Pacific Restless Legs Syndrome Market Size by Region (2019-2024) & (US$ Million)
    Table 39. Asia-Pacific Restless Legs Syndrome Market Size by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Restless Legs Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Latin America Restless Legs Syndrome Market Size by Country (2019-2024) & (US$ Million)
    Table 42. Latin America Restless Legs Syndrome Market Size by Country (2025-2030) & (US$ Million)
    Table 43. Middle East & Africa Restless Legs Syndrome Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Middle East & Africa Restless Legs Syndrome Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Middle East & Africa Restless Legs Syndrome Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Boehringer Ingelheim GmbH Company Detail
    Table 47. Boehringer Ingelheim GmbH Business Overview
    Table 48. Boehringer Ingelheim GmbH Restless Legs Syndrome Product
    Table 49. Boehringer Ingelheim GmbH Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 50. Boehringer Ingelheim GmbH Recent Development
    Table 51. UCB SA Company Detail
    Table 52. UCB SA Business Overview
    Table 53. UCB SA Restless Legs Syndrome Product
    Table 54. UCB SA Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 55. UCB SA Recent Development
    Table 56. Astellas Company Detail
    Table 57. Astellas Business Overview
    Table 58. Astellas Restless Legs Syndrome Product
    Table 59. Astellas Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 60. Astellas Recent Development
    Table 61. Arbor Pharmaceuticals Company Detail
    Table 62. Arbor Pharmaceuticals Business Overview
    Table 63. Arbor Pharmaceuticals Restless Legs Syndrome Product
    Table 64. Arbor Pharmaceuticals Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 65. Arbor Pharmaceuticals Recent Development
    Table 66. GlaxoSmithKline plc. Company Detail
    Table 67. GlaxoSmithKline plc. Business Overview
    Table 68. GlaxoSmithKline plc. Restless Legs Syndrome Product
    Table 69. GlaxoSmithKline plc. Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 70. GlaxoSmithKline plc. Recent Development
    Table 71. Ligand Pharmaceuticals Incorporated Company Detail
    Table 72. Ligand Pharmaceuticals Incorporated Business Overview
    Table 73. Ligand Pharmaceuticals Incorporated Restless Legs Syndrome Product
    Table 74. Ligand Pharmaceuticals Incorporated Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 75. Ligand Pharmaceuticals Incorporated Recent Development
    Table 76. axxonis Pharma AG Company Detail
    Table 77. axxonis Pharma AG Business Overview
    Table 78. axxonis Pharma AG Restless Legs Syndrome Product
    Table 79. axxonis Pharma AG Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 80. axxonis Pharma AG Recent Development
    Table 81. Kyowa Hakko Kirin Co. Company Detail
    Table 82. Kyowa Hakko Kirin Co. Business Overview
    Table 83. Kyowa Hakko Kirin Co. Restless Legs Syndrome Product
    Table 84. Kyowa Hakko Kirin Co. Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 85. Kyowa Hakko Kirin Co. Recent Development
    Table 86. Jazz Pharmaceuticals, Inc. Company Detail
    Table 87. Jazz Pharmaceuticals, Inc. Business Overview
    Table 88. Jazz Pharmaceuticals, Inc. Restless Legs Syndrome Product
    Table 89. Jazz Pharmaceuticals, Inc. Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 90. Jazz Pharmaceuticals, Inc. Recent Development
    Table 91. Omeros Corporation Company Detail
    Table 92. Omeros Corporation Business Overview
    Table 93. Omeros Corporation Restless Legs Syndrome Product
    Table 94. Omeros Corporation Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 95. Omeros Corporation Recent Development
    Table 96. Manhattan Pharmaceuticals Company Detail
    Table 97. Manhattan Pharmaceuticals Business Overview
    Table 98. Manhattan Pharmaceuticals Restless Legs Syndrome Product
    Table 99. Manhattan Pharmaceuticals Revenue in Restless Legs Syndrome Business (2019-2024) & (US$ Million)
    Table 100. Manhattan Pharmaceuticals Recent Development
    Table 101. Research Programs/Design for This Report
    Table 102. Key Data Information from Secondary Sources
    Table 103. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Restless Legs Syndrome Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Restless Legs Syndrome Market Share by Type: 2023 VS 2030
    Figure 3. Pharmacological Therapy Features
    Figure 4. Non-Pharmacological Therapy Features
    Figure 5. Global Restless Legs Syndrome Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 6. Global Restless Legs Syndrome Market Share by Application: 2023 VS 2030
    Figure 7. Below 35 Years Old Case Studies
    Figure 8. From 35 to 50 Years Old Case Studies
    Figure 9. Above 50 Years Old Case Studies
    Figure 10. Restless Legs Syndrome Report Years Considered
    Figure 11. Global Restless Legs Syndrome Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Restless Legs Syndrome Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Restless Legs Syndrome Market Share by Region: 2023 VS 2030
    Figure 14. Global Restless Legs Syndrome Market Share by Players in 2023
    Figure 15. Global Top Restless Legs Syndrome Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Restless Legs Syndrome as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Restless Legs Syndrome Revenue in 2023
    Figure 17. North America Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Restless Legs Syndrome Market Share by Country (2019-2030)
    Figure 19. United States Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. Canada Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. Europe Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Europe Restless Legs Syndrome Market Share by Country (2019-2030)
    Figure 23. Germany Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. France Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. U.K. Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. Italy Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. Russia Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Nordic Countries Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Asia-Pacific Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Asia-Pacific Restless Legs Syndrome Market Share by Region (2019-2030)
    Figure 31. China Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Japan Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. South Korea Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Southeast Asia Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. India Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Australia Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Latin America Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Latin America Restless Legs Syndrome Market Share by Country (2019-2030)
    Figure 39. Mexico Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Brazil Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Middle East & Africa Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa Restless Legs Syndrome Market Share by Country (2019-2030)
    Figure 43. Turkey Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Saudi Arabia Restless Legs Syndrome Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Boehringer Ingelheim GmbH Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 46. UCB SA Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 47. Astellas Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 48. Arbor Pharmaceuticals Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 49. GlaxoSmithKline plc. Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 50. Ligand Pharmaceuticals Incorporated Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 51. axxonis Pharma AG Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 52. Kyowa Hakko Kirin Co. Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 53. Jazz Pharmaceuticals, Inc. Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 54. Omeros Corporation Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 55. Manhattan Pharmaceuticals Revenue Growth Rate in Restless Legs Syndrome Business (2019-2024)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation
    Figure 58. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Novocure

SIMILAR REPORTS